RNAi-induced K-Ras Gene Silencing Suppresses Growth of EC9706 Cells and Enhances Chemotherapy Sensitivity of Esophageal Cancer

  • Wang, Xin-Jie (Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Zhengzhou University) ;
  • Zheng, Yu-Ling (Department of Oncology, The First Affiliated Hospital of Zhengzhou University) ;
  • Fan, Qing-Xia (Department of Oncology, The First Affiliated Hospital of Zhengzhou University) ;
  • Zhang, Xu-Dong (Department of Oncology, The First Affiliated Hospital of Zhengzhou University)
  • 발행 : 2012.12.31


To analyze the growth, proliferation, apoptosis, invasiveness and chemotherapy sensitivity of EC9706 cells after K-Ras gene silencing, an expression carrier pSilencer-siK-Ras was constructed, and the EC9706 cell line was transfected using a liposome technique. Six groups were established: Control, siRNA NC (transfected with empty vector pSilencer2.1); Ras siRNA (transfected with pSilencer-siK-Ras2); Paclitaxel; Paclitaxel + siRNA NC; and Ras siRNA + Paclitaxel. After the treatment, RT-PCR, Western blotting, MTT assay, flow cytometry and the Transwell technique were used to assess expression of K-Ras mRNA and protein in EC9706 cells, as well as cell growth, proliferation, apoptosis and invasiveness. The effect of Paclitaxel chemotherapy was also tested. pSilencer-siK-Ras2 effectively down-regulated expression of K-Ras mRNA and protein in EC9706 cells, growth being significantly inhibited. Flow cytometry indicated obvious apoptosis of cells in the experimental group, with arrest in the G1 phase; cell migration ability was also reduced. After pSilencer-siK-Ras2 transfection or the addition of Paclitaxel, EC9706 cells were suppressed to different extents; the suppressive effect was strengthened by combined treatment. The results suggested that RNAi-induced K-Ras gene silencing could enhance chemotherapy sensitivity of esophageal cancer.


  1. Pu H, Chen X, Li X, et al (2011). Expression of hMLH1 and RASSF1A in esophageal cancer tissues and its relationship with prognosis. World Chin J Digestol, 19, 1347-52.
  2. Quinlan MP, Settleman J (2008). A KRas-specific Function in cancer Initiation. Chin J Cancer, 27, 673.
  3. Riely GJ, Marks J, Pao W (2009). K-RAS mutations in non-small cell lung cancer. Proc Am Thorac Soc, 6, 201-5.
  4. Schimanski CC, Zimmermann T, Schmidtmann I, et al (2010). K-Ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFR alpha in colorectal cancer. Int J Colorectal Dis, 25, 181-6.
  5. Shen YM, Yang XC, Yang C, Shen JK (2008). Enhanced therapeutic effects for human pancreatic cancer by application K-Ras and IGF-IR antisense Oligodeoxynucleotids. World J Gastroentero, 14, 5176-85.
  6. Song MS, Chang JS, Song SJ, et al (2005). The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles. J Biol Chem, 280, 3920-7.
  7. Stella G, Rojas FL, Barone C, et al (2009). KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients [C], ASCO GICancers Symposium, Abstr34.
  8. Tanaka T, Ishiguro H, Kuwabara Y, et al (2010). Vascular endothelial growth factor C in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res, 29, 83.
  9. Wang X, Zheng Y, Fan Q (2011). Ras pathway and the activated expression of cyclin D1 in esophageal squamous cell carcinoma. J Third Military Med University, 33, 2626-8.
  10. Wang YX, Gao L, Ji ZZ (2007). Inhibitaary effects of antisense oligonucleoti-de specific to K-Ras pointmutation on the target gene expression in uman pancreatic carcinoma cells [J] Chin Med J, 120, 1448.
  11. Yoo YA, Na AR, Lee MS, et al (2006). RASSF1A suppresses oncogenic H-Ras-induced c-Jun N-terminal kinase activation. Int J Oncol, 29, 1541-7.
  12. Zhang TW, Wang SF, Cong DG, et al (2007). Suppression of RASSF1A gene on human esophageal carcinoma cells: experiments in vitroR and in vivo. National Med J China, 87, 1214-6.
  13. Zhong YQ, Xia ZS, Fu YR, et al (2010). Knockdown of Htert by siRNA suppresses growth of Capan-2 human pancreatic cancer cell via the inhibition of expressions of Bcl-2 and COX-2. J Dig Dis, 11, 176-84.
  14. Akkiprik M, Celikel CA, Düsünceli F, et al (2008). Relationship between overexpression of Ras p21 oncoprotein and K-Ras codon 12 and 13 mutations in Trukish colorectal cancer patients. Turk J Gastroenterol, 19, 22-7.
  15. Bivona TG, Quatela SE, Bodemann BO, et al (2006). PKC regulates a farne-syl-electro-soatic switch on K-Ras that promotes its association with Bcl-X2 on mitochondria and induces apoptosis [J]. Molecular Cell, 21, 481.
  16. Chen Y, Lan Z, Hui Q, Li B, Yang Y (2008). Expression of RASSF1A and CyclinD1 in tissues with gastric mucosa lesion and their relationship. World Chin J Digestology, 16, 2604-9.
  17. Cong DG, Wang SF, Zhang TW (2006). mRNA expression of RASSF1A in esophageal squamous cell carcinoma and clinical significance thereof. Nat Med J China, 86, 1624-7.
  18. Leung RK, Whittaker PA (2005). RNA interference:from gene silencing to gene-specific therapeutics. Pharmacol Ther, 107, 222-39.
  19. Li J, Zhao Z, Zhou Q, Wang L (2009). Expression of Ras protein in esophageal cancer and precancerous lesions. Chin J Clin Oncol Rehab, 6, 11-13.
  20. Lo PH, Xie D, Chan KC, et al (2007). Reduced expression of RASSF1A in esophageal and naso-pharyngeal carcinomas significantly correlates with tumor stage. Cancer Lett, 257, 199-205.
  21. Pijnenborg JM, Dam-de Veen GC, Kisters N, et al (2007). RASSF1A methylation and K-Ras and B-rafmutations and recurrent endometrial cancer. Ann Oncol, 18, 491-7.

피인용 문헌

  1. Biodegradable nanoparticles as siRNA carriers for in vivo gene silencing and pancreatic cancer therapy vol.5, pp.18, 2017,